Who is sponsoring NCT04799769?

NCT04799769 is sponsored by Vivasure Medical Limited.

What drugs are being tested in NCT04799769?

Interventions in NCT04799769: Percutaneous arterial closure device.

What condition does NCT04799769 study?

NCT04799769 studies Percutaneous Arteriotomy Closure.

Is NCT04799769 still recruiting?

NCT04799769 is currently status unknown. Last updated 12 April 2022.

Last reviewed 2022-04-12 · How we verify

NCT04799769

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER V Study

Status unknown NA Last updated 12 April 2022

What this trial tests

NA trial testing Percutaneous arterial closure device in Percutaneous Arteriotomy Closure in 90 participants. Status unknown.

Timeline

10 March 2021

Primary endpoint
10 January 2023

10 March 2023

Quick facts

Lead sponsor	Vivasure Medical Limited
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	10 March 2021
Primary completion	10 January 2023
Estimated completion	10 March 2023
Sites	5 locations across Netherlands, Germany

Drugs / interventions tested

Percutaneous arterial closure device

Conditions studied

Percutaneous Arteriotomy Closure — all drugs for Percutaneous Arteriotomy Closure →

Sponsor

Vivasure Medical Limited

Who can join

18 and older, any sex, with Percutaneous Arteriotomy Closure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be a prospective, multi-centred, non-randomized study to investigate the safety and performance of the PerQseal® + in up to 90 patients in up to 8 European investigational sites. The PerQseal® + shall be indicated for the percutaneous closure of femoral artery punctures and to induce arterial haemostasis in patients undergoing endovascular procedures requiring an arteriotomy created with 14 - 22F sheaths (arteriotomy up to 26 F).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Frontier V Study: Evaluating the Safety and Clinical Performance of a Large-Bore Vascular Closure Device After Femoral Arterial Access.
Frerker C, Schwindt A, Schmidt A, Schmidt T, et al · · 2025 · cited 1× · PMID 40343429 · DOI 10.1002/ccd.31574

Verify or expand the search:

Other Vivasure Medical Limited trials

Trials by the same sponsor.

NCT05163548 — PerQseal®+ Early Feasibility Study · NA · completed
NCT04818541 — PerQseal® Impella Early Feasibility Study · NA · completed
NCT03423602 — Safety and Performance Study of Large Hole Vascular Closure Device FIV · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04799769 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vivasure Medical Limited
Last refreshed: 12 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04799769.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing